Roche Tasmar

Anti-Parkinson's agent Tasmar (tolcapone) is no longer being promoted, Roche says. The company received a letter from FDA's ad division Aug. 2 objecting to the dissemination of introductory promotional materials, including the outdated claim that Tasmar is the "only COMT inhibitor." Roche told FDA that it ceased all promotion of Tasmar in September 2000. The drug was withdrawn in Europe and relabeled in the U.S. in 1998 due to liver toxicity reports